



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 22, 2019

John Melo  
President and Chief Executive Officer  
Amyris, Inc.  
5885 Hollis Street, Suite 100  
Emeryville, CA 94608

**Re: Amyris, Inc.**  
**Registration Statement on Form S-1**  
**Filed November 13, 2019**  
**File No. 333-234661**

Dear Mr. Melo:

We have limited our review of your registration statement to those issues we have addressed in our comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments.

Registration Statement on Form S-1

General

1. Given the nature and size of the transaction being registered, advise the staff of the company's basis for determining that the offering is eligible to be made on a shelf basis under Rule 415(a)(1)(i).

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

John Melo  
Amyris, Inc.  
November 22, 2019  
Page 2

You may contact Joseph McCann at (202) 551-6262 or Celeste Murphy at (202) 551-3257 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Ryan Mitteness